Will Novo’s LEADER Trial Move GLP-1 To The Front Line In High-Risk Diabetes?

Novo Nordisk AS has an impressive victory with a benefit demonstrated in the LEADER cardiovascular outcomes study of its GLP-1 agonist Victoza in high-risk type 2 diabetes, but the real test could be whether the magnitude of benefit is big enough to shift practice and expand use beyond the class’s tiny base.

The company reported that once-daily Victoza (liraglutide) reduced the cardiovascular event rate compared to standard of care in diabetes patients...